Dashtipour, K.; Lee, H.S.; Ellenbogen, A.; Kazerooni, R.; Gross, T.M.; Hollander, D.A.; Gallagher, C.J.
Reply to Trosch et al. Comment on “Dashtipour et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins 2024, 16, 442”. Toxins 2025, 17, 191.
https://doi.org/10.3390/toxins17040191
AMA Style
Dashtipour K, Lee HS, Ellenbogen A, Kazerooni R, Gross TM, Hollander DA, Gallagher CJ.
Reply to Trosch et al. Comment on “Dashtipour et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins 2024, 16, 442”. Toxins. 2025; 17(4):191.
https://doi.org/10.3390/toxins17040191
Chicago/Turabian Style
Dashtipour, Khashayar, Han S. Lee, Aaron Ellenbogen, Rashid Kazerooni, Todd M. Gross, David A. Hollander, and Conor J. Gallagher.
2025. "Reply to Trosch et al. Comment on “Dashtipour et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins 2024, 16, 442”" Toxins 17, no. 4: 191.
https://doi.org/10.3390/toxins17040191
APA Style
Dashtipour, K., Lee, H. S., Ellenbogen, A., Kazerooni, R., Gross, T. M., Hollander, D. A., & Gallagher, C. J.
(2025). Reply to Trosch et al. Comment on “Dashtipour et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins 2024, 16, 442”. Toxins, 17(4), 191.
https://doi.org/10.3390/toxins17040191
